Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;207(4):1632-1637.
doi: 10.1111/bjh.70054. Epub 2025 Jul 30.

Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies

Abi Vijenthira  1   2 , Sita Bhella  1   2 , Katrina Hueniken  1 , Allison M Wilkin  3 , Michael Sebag  4 , Peng Wang  5 , Lisa K Hicks  2   6 , Annette E Hay  7 , Sarit Assouline  8 , Amaris Balitsky  9   10 , Graeme Fraser  9   10 , Joy Mangel  11 , Carolyn Owen  12 , Anthony Reiman  13 , Laurie Sehn  14 , Heather Sutherland  15 , Corey Arnold  16 , Tamara Leite  3 , Erinn McCarthy  1 , Angela Crawley  3 , Curtis Cooper  3   17 , Marc-Andre Langlois  16 , C Arianne Buchan  3   17 ; VIP Study Investigators
Affiliations

Incremental immunogenicity of multiple doses of SARS-CoV-2 vaccination in patients with haematological malignancies

Abi Vijenthira et al. Br J Haematol. 2025 Oct.
No abstract available

Keywords: clinical studies; malignant haematology; vaccines.

PubMed Disclaimer

Conflict of interest statement

AV, KH, AW, PW, LKH, GF, JM, CO, AR, HS, CA, TL, EM, AC, CC, M‐AL, CAB: None; SB: Gilead Sciences Inc.: consulting or advisory and travel reimbursement; MS: Research Funding: Janssen; Advisory Boards: Janssen, Amgen, Pfizer, Kite, Sanofi, BMS; SA: Research Funding: Novartis; Consultancy: Abbvie, Beigene, Astra Zeneca, Roche Genentech, Novartis, Janssen, Daichi Sankyo; AB: Honoraria: Beigene, Kite/Gilead, Sobi, BMS; research funding: Novartis; AEH has received institutional research funding from J&J, Abbvie, Merck, Seattle Genetics, Karyopharm, Incyte, BMS, and Roche; LS: Honoraria: Abbvie; Amgen; AstraZeneca; Beigene; BMS/Celgene; Genmab; Kite/Gilead; Incyte; Janssen; Merck; Seagen; F. Hoffmann‐La Roche Ltd.; Genentech, Inc.; Research Funding: F. Hoffman‐La Roche Ltd.; Genentech, Inc.; Teva; Consultancy: AbbVie; Amgen; AstraZeneca; Beigene; BMS/Celgene; Genmab; Kite/Gilead; Incyte; Janssen; Merch; Seagen; F. Hoffman‐La Roche Ltd.; Genentech, Inc.

References

    1. Gong IY, Vijenthira A, Powis M, Calzavara A, Patrikar A, Sutradhar R, et al. Association of COVID‐19 vaccination with breakthrough infections and complications in patients with cancer. JAMA Oncol. 2023;9(3):386–394. - PMC - PubMed
    1. Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, et al. Outcomes of patients with hematologic malignancies and COVID‐19: a systematic review and meta‐analysis of 3377 patients. Blood. 2020;136(25):2881–2892. - PMC - PubMed
    1. Figueiredo JC, Merin NM, Hamid O, Choi SY, Lemos T, Cozen W, et al. Longitudinal SARS‐CoV‐2 mRNA vaccine‐induced humoral immune responses in patients with cancer. Cancer Res. 2021;81(24):6273–6280. - PMC - PubMed
    1. Hillyer A, Quint A, Ghassemian A, Joh‐Carnella N, Knauer MJ, Dawd D, et al. Serologic response to vaccine for COVID‐19 in patients with hematologic malignancy: a prospective cohort study. Clin Lymphoma Myeloma Leuk. 2024;24(5):305–315. - PubMed
    1. Jiménez M, Fernández‐Naval C, Navarro V, Novoa S, Martinez‐Gallo M, Medina D, et al. Kinetics of cellular and humoral immunogenicity and effectiveness of SARS‐CoV‐2 booster vaccination in hematologic neoplasms. Am J Hematol. 2023;98(8):1204–1213. - PubMed

LinkOut - more resources